Abstract
Get full access to this article
View all access options for this article.
References
1.
Sarepta Therapeutics. Sarepta therapeutics provides program update for SRP-9001, its investigational gene therapy for the treatment of
Duchenne muscular dystrophy. 2020. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-provides-program-update-srp-9001-its (last accessed
September 20 , 2020
).
2.
Mast
J. S
,
arepta CEO Doug Ingram pins gene therapy delay on Covid-burdened
FDA
, can't offer timeline for fix. Endpoints. 2020. https://endpts.com/sarepta-ceo-doug-ingram-pins-gene-therapy-delay-on-covid-burdened-fda-cant-offer-timeline-for-fix/ (last accessed
September 20 , 2020
).
3.
REGENXBIO and The Trustees of The University of
Pennsylvania v
.
Sarepta Therapeutics and Sarepta Therapeutics Three
LL
C, 1:20-cv-01226-UNA,
filed at
U.S
.
District
Court
,
District of
Delaware
. https://ecf.ded.uscourts.gov/doc1/04314950499 (last accessed
September 21 , 2020
).
4.
Catalent. Catalent invests $130 million to add additional manufacturing capacity at its gene therapy campus in Harmans, Maryland. 2020. https://www.catalent.com/catalent-news/catalent-invests-130-million-to-add-additional-manufacturing-capacity-at-its-gene-therapy-campus-in-harmans-maryland/ (last accessed
September 18 , 2020
).
5.
Taysha Gene Therapies via
U.S
.
Securities and Exchange
Commission
. Prospectus. September 23, 2020. https://ir.tayshagtx.com/static-files/72058f58-ad4f-4a41-8a87-50044ea25a08 (last accessed
October 1 , 2020
).
6.Novartis.
AveXis renamed Novartis Gene
Therapies
,
signifying the growing importance of gene therapy to
Novartis corporate strategy
. 2020. https://www.novartis.com/news/avexis-renamed-novartis-gene-therapies-signifying-growing-importance-gene-therapy-novartis-corporate-strategy (last accessed
September 18 , 2020
).
7.
Bulik
B. S.
,
With new
AveXis name
, Novartis spotlights marquee role for gene therapy business.
Fierce
Pharma
. 2020 . https://www.fiercepharma.com/marketing/novartis-changes-avexis-name-to-novartis-gene-therapies-retires-beleaguered-brand-and – SePT4 (last accessed
September 18 , 2020
).
8.GenSight Biologics. GenSight biologics submits EU marketing authorisation application for LUMEVOQ® gene therapy to treat vision loss due to Leber hereditary optic neuropathy (LHON). 2020 . https://www.gensight-biologics.com/2020/09/15/gensight-biologics-submits-eu-marketing-authorisation-application-for-lumevoq-gene-therapy-to-treat-vision-loss-due-to-leber-hereditary-optic-neuropathy-lhon/ (last accessed
September 18 , 2020
).
9.
Raper
V. G
ene therapy company develops streamlined manufacturing model. Genetic Engineering &
Biotechnology
News
. 2020. https://www.genengnews.com/topics/bioprocessing/gene-therapy-company-develops-streamlined-manufacturing-model/ (last accessed
September 21 , 2020
).